Zodasiran is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase II drugs for Mixed Dyslipidemia have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zodasiran’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zodasiran overview
AROANG-3 is under development for the treatment of dyslipidemic patients including familial hypercholesterolemia including homozygous familial hypercholesterolemia and heterozygous familial hypercholesterolemia (heFH), severe hypertriglyceridemia, familial chylomicronemia syndrome and mixed dyslipidemia. It is administered through subcutaneous route. The therapeutic candidate is a siRNA acts by targeting angiopoietin-like 3 protein (ANGPTL3). The drug candidate is developed based on targeted RNAi molecule (TRiM) platform.
Arrowhead Pharmaceuticals overview
Arrowhead Pharmaceuticals (Arrowhead) is a biotech company that develops and commercializes gene silencing therapeutics. The company utilizes RNA chemistries and TRiM platform to target and silence disease-causing genes. Its pipeline products include ARO-APOC3, ARO-ANG3, Olpasiran, GSK-4532990, ARO-PNPLA3, ARO-RAGE, ARO-MMP7, ARO-MUC5AC, Fazirsiran, ARO-HB, ARO-DUX4 and ARO-DM1. Arrowhead product indications include hypertriglyceridemia, dyslipidemia, cardiovascular disease, nonalcoholic steatohepatitis, inflammatory, idiopathic pulmonary fibrosis, idiopathic pulmonary fibrosis, much-obstructive, alpha-1 liver disease, hepatitis b, facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1. The company operates lab facilities in San Diego, California and Madison, Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
For a complete picture of Zodasiran’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
